Abraxis BioScience (ABII) Announces Positive Data At ASCO on ABRAXANE

June 1, 2009 8:29 AM EDT

Abraxis BioScience, Inc. (NASDAQ: ABII) announced results at ASCO from two ongoing studies evaluating the chemotherapy agent ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of a particularly hard-to-treat type of cancer, metastatic melanoma.

In one study that evaluated ABRAXANE (150 mg/m2) given in combination with the targeted agent bevacizumab (10 mg/kg), 74 percent of patients were alive without their disease progressing four months after treatment, with a median progression-free survival (PFS) of 5.8 months. In addition, 91 percent of patients were alive six months after treatment with the ABRAXANE/bevacizumab combination and the one year survival rate was 68 percent.

In a second study, previously untreated patients who received combination treatment with ABRAXANE (100 mg/m2) and the standard chemotherapy carboplatin (AUC 2) achieved a median overall survival of 11.1 months. Patients who received the same combination treatment with ABRAXANE but had received prior chemotherapy had an overall survival rate of 10.9 months.

More from Release

Related Categories

FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?